Bioasis Technologies Inc. Stock price

Equities

BTI

CA09064N1033

Biotechnology & Medical Research

Delayed Toronto S.E. 12:00:00 2024-03-21 pm EDT 5-day change 1st Jan Change
0.005 CAD 0.00% Intraday chart for Bioasis Technologies Inc. 0.00% 0.00%
Sales 2021 4.08M 3.01M Sales 2022 37.72K 27.86K Capitalization 19.32M 14.27M
Net income 2021 - 0 Net income 2022 -2M -1.48M EV / Sales 2021 5.7 x
Net cash position 2021 2.62M 1.94M Net Debt 2022 171K 126K EV / Sales 2022 517 x
P/E ratio 2021
35.1 x
P/E ratio 2022
-6.46 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 97.95%
More Fundamentals * Assessed data
Dynamic Chart
Bioasis Technologies Inc. Announces Terminating the Non-Exclusive Research Collaboration and Licensing Agreement with Chiesi Farmaceutici S.P.A CI
Bioasis Technologies Slumps 25% As Provides Update on Financial Position MT
Bioasis Technologies Provides Update on Financial Position; Down 11% on Friday MT
Bioasis Technologies Explores and Evaluates Strategic Alternatives CI
Midatech Pharma plc cancelled the acquisition of Bioasis Technologies Inc.. CI
Bioasis Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2022 CI
Midatech Pharma plc entered into a definitive agreement to acquire Bioasis Technologies Inc. from The Lind Partners, LLC and others for $5.5 million. CI
Bioasis Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2022 CI
Bioasis Technologies Inc. Reports Earnings Results for the First Quarter Ended May 31, 2022 CI
Bioasis Technologies Buys Phase 2 Ready Rare Orphan EGF Assets From Norwegian Company MT
Bioasis Technologies Inc. Reports Earnings Results for the Full Year Ended February 28, 2022 CI
Bioasis Technologies Inc. Auditor Raises 'Going Concern' Doubt CI
Bioasis Technologies and Neuramedy of South Korea Enter into Research Collaboration and License Agreement MT
Bioasis Technologies Inc. and Neuramedy Co Ltd Enter into Research Collaboration and License Agreement CI
Bioasis Technologies to Collaborate on Research with Johnson & Johnson's Janssen Biotech Subsidiary MT
More news
1 month
0.01
Extreme 0.005
0.01
Current year
0.01
Extreme 0.005
0.01
1 year
0.01
Extreme 0.005
0.02
3 years
0.01
Extreme 0.005
0.44
5 years
0.00
Extreme 0
0.70
10 years
0.00
Extreme 0
2.05
More quotes
Managers TitleAgeSince
Chief Executive Officer - 17-09-20
Director of Finance/CFO - 21-06-30
Chief Tech/Sci/R&D Officer - 11-12-31
Members of the board TitleAgeSince
Director/Board Member 59 -
Director/Board Member 65 18-07-26
Chief Executive Officer - 17-09-20
More insiders
Date Price Change Volume
24-03-21 0.005 +∞% 0
24-03-20 - -100.00% 814

Delayed Quote Toronto S.E., March 21, 2024 at 12:00 pm EDT

More quotes
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.
More about the company
  1. Stock
  2. Equities
  3. Stock Bioasis Technologies Inc. - Toronto S.E.